会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • AZIDE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF
    • 维多利亚ZIDI
    • EP2315802A4
    • 2012-04-18
    • EP09803298
    • 2009-04-20
    • 3M INNOVATIVE PROPERTIES CO
    • JOHANNESSEN BIRGERMANZARA ANTHONY PGOODNER ARON Y
    • C08K5/28C07C247/04C07C247/12
    • C07C247/04C07C271/12C08K5/28C08K2201/014
    • Azide compositions selected from i) UOCR2CR2N3 wherein U is D, or a urethane (—CO—NR2) and R is independently H, D, or an organic group; ii) R′2NCR2CR2N3 or A-R′3NCR2CR2N3 wherein R′ is an organic group and A is an anion; or iii) G(N3)m wherein m is an integer from 2 to about 10 and G is a m-valent organic group wherein at least two of the azido groups are connected via aliphatic carbon atoms wherein G may contain organic groups, and uses thereof are described. Specifically, the azide compositions selected from the group consisting of: N3CH2CH2OCH2CHOHCH2N3, CH3OCH2CHOHCH2N3, CH3OCH2CH(OCONHC4H9)CH2N3, N3CH2CH2O[CH2CH(CH2N3)O]6H, CH3CH2C[CH2(OCH2CH(CH2N3))2OCOCH3]3N3CH2CH2OCONH(CH2)6NHCOOCH2CH2N3, (CH3)3CNHCOOCH2CH2N3, n-C4H9NDCOOCH2CH2N3, C6H5N—HCOOCH2CH2N3, C4F9OCFCF3NDCOOCH2CH2N3, DOCH2CH2N3, and [(CH3)3NCH2CH2N3]+I are described.
    • 选自i)UOCR2CR2N3,其中U是D的叠氮化物组合物或氨基甲酸酯(-CO-NR 2),R独立地是H,D或有机基团; ii)R'2NCR2CR2N3或A-R'3NCR2CR2N3,其中R'是有机基团,A是阴离子; 或iii)G(N 3)m,其中m为2至约10的整数,G为m价有机基团,其中至少两个叠氮基通过脂族碳原子连接,其中G可以含有有机基团,并且使用 描述。 具体地,选自N 3 CH 2 CH 2 OCH 2 CHOHCH 2 N 3,CH 3 OCH 2 CHOHCH 2 N 3,CH 3 OCH 2 CH(OCONHC 4 H 9)CH 2 N 3,N 3 CH 2 CH 2 O [CH 2 CH(CH 2 N 3)O] 6H,CH 3 CH 2 C [CH 2(OCH 2 CH(CH 2 N 3))2 OCO 3] 3 N 3 CH 2 CH 2 OCONH(CH 2)6 NHCOOCH 2 CH 2 N 3, CH3)3CNHCOOCH2CH2N3,n-C4H9NDCOOCH2CH2N3,C6H5N-HCOOCH2CH2N3,C4F9OCFCF3NDCOOCH2CH2N3,DOCH2CH2N3和[(CH3)3NCH2CH2N3] + I。
    • 6. 发明公开
    • Synthesis for the preparation of porphobilinogen, the compound as such as stabilized salt and intermediates thereof
    • 一种制备胆色素原的,该化合物本身为稳定的盐和它们的中间体的方法
    • EP1357110A1
    • 2003-10-29
    • EP02009121.1
    • 2002-04-24
    • Neier, Reinhard
    • Neier, ReinhardSoldermann-Pissot, Carole
    • C07D207/32C12P17/10C07F7/18C07C247/12
    • C07D207/337C07F7/1852C07F7/188C12P17/10Y02P20/55
    • The invention relates to a new inventive process sequence of steps a) to e) as claimed in Claim 1 for the preparation of porphobilinogen and intermediates per se as important precursors such as 3-[4-methoxycarbonylmethyl-5-(protected amino-methyl)-1 H-pyrrol-3-yl]-propionic acid methyl ester of formula 7
      wherein R is a protective group,
      and 3-[4-Carboxymethyl-5-(protected amino-methyl)-1 H-pyrrol-3-yl]-propionic acid di-alkali metal salt of formula 8
      and especially 3-[4-carboxymethyl-5-(phenylacetyl-amino-methyl)- 1H-pyrrol-3-yl]-propionic acid di-lithium salt of formula 8a
      and of carboxylate 4-(2-carboxy-ethyl)-3-carboxymethyl-1H-pyrrrol-2-yl-methyl-ammonium of formula 9
      and of phenylacetate 4-(2-carboxy-ethyl)-3carboxymethyl-1 H-pyrrol-2-ylmethyl-ammonium of formula 9a
      and the use thereof for the preparation of porphobilinogen.
    • 本发明涉及到的步骤a)至e)的新发明的工艺顺序,如权利要求1要求保护的用于胆色素原和中间体本身的制备作为重要的前体:例如3- AE4甲氧羰基甲基-5-(保护的氨基 - 甲基) - 式7 worin的R 1个H-吡咯-3-ylÜ - 丙酸甲酯为保护基,和3- AE4羧甲基-5-(保护的氨基 - 甲基)-1H-吡咯-3-ylÜ - 丙酸二碱式的金属盐8 和爱尤其是3- AE4羧甲基-5-(苯基乙酰基氨基 - 甲基) - 式8a的1H-吡咯-3-丙酸ylÜ二锂盐< CHEM>和的羧酸酯4-(2-羧基 - 乙基)式9 和苯乙酸4- -3羧甲基-1H-pyrrrol -2-基甲基 - 铵(2-羧基 - 乙基)-3carboxymethyl -1H-吡咯-2-基甲基 - 铵式9a中及其用于胆色素原的制备中的用途的。